Navigation Links
Pharsight to Present on Its Vision for Modeling and Simulation Software at PAGE Annual Meeting

Dr. Robert Leary Will Discuss Computational Methods for Model Evaluation;

Dr. Mike Dunlavey Will Present Simplified Programming Approaches of

Population Model User Interfaces

MOUNTAIN VIEW, Calif., June 12 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Pharsight software development experts will deliver two poster presentations at the Population Approach Group in Europe (PAGE) 17th Annual Meeting in Marseille, France from June 18-20, 2008. Robert Leary, Ph.D., fellow, Pharsight Research and Development Group, will present work on computational methods for model evaluation. Mike Dunlavey, Ph.D., fellow, Pharsight Research and Development Group, will present new approaches on simplified programming of population model user interfaces.

These poster sessions will provide a forum for pharmaceutical scientists from industry and academia to have scientific discussion and collaborative exchange on model-based approaches. Pharsight's two presentations are:

-- June 18: Simplified Programming of Population Model User Interfaces.

Dr. Dunlavey will present a differential execution algorithm that

allows a "painting" paradigm (called Dynamic Dialogs) as an alternative

to event-based programming. This programming paradigm simplifies

implementation of software products with complex graphical displays and

user interface requirements.

-- June 19: Nonparametric Analogs to POSTHOC Estimates for Exploratory

Data Analysis. Dr. Leary will present a nonparametric model evaluation

method to complement commonly used approaches for exploratory data

analysis of possible covariate relationships. This work builds on

applied research presented by industry colleagues at past PAGE

conferences and on Dr. Leary's earlier work in the area of nonlinear

mixed effects (NLME) analysis.

"The development of advanced computational tools and next generation programming languages are integral to the continued growth of model-based drug development," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "We continue to develop technology to remain on the cutting edge of the industry and to create solutions that meet our customers' specific needs. Pharsight looks forward to presenting on specific elements of our vision for the future of model-based drug development, and is proud to again have such a wide presence at PAGE this year."

Additional information about PAGE can be found at

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this document are trademarks or registered trademarks of their respective companies or organizations.

SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Pharsight to Present on Oncology Modeling and Simulation at PAGE Annual Meeting
2. Pharsight Invited to Present on Modeling and Simulation at ARCS Australia Scientific Congress
3. Pharsight Invited to Present on Antiviral Modeling and Simulation at DIA Adherence Workshop
4. Pharsight Strengthens Senior Management Team
5. Pharsight Announces Fiscal Fourth Quarter 2008 and Year End Earnings Release Date and Conference Call
6. Pharsight Signs New Diabetes Meta-Database Customer
7. Pharsight to Present at eClinical Forum
8. Pharsight to Host Webinar on Hepatitis C Virus (HCV) and HIV Drug-Disease Modeling
9. FDA and Pharsight Continue to Collaborate Under CRADA
10. Pharsight to Present at DIA Cardiac Safety Conference on December 4, 2007
11. Pharsight Achieves $7.3 Million in Quarterly Revenue
Post Your Comments:
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
Breaking Medicine Technology: